IONS vs. ALNY
IONS (Ionis Pharmaceuticals, Inc.) and ALNY (Alnylam Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, IONS returned 3.21%/yr vs 11.28%/yr for ALNY. Their 0.47 correlation means their historical movements had little consistent relationship.
Performance
IONS vs. ALNY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IONS achieves a -34.56% return, which is significantly higher than ALNY's -48.32% return. Over the past 10 years, IONS has underperformed ALNY with an annualized return of 3.21%, while ALNY has yielded a comparatively higher 11.28% annualized return.
IONS
- 1D
- -2.83%
- 1M
- -36.71%
- 6M
- -37.38%
- YTD
- -34.56%
- 1Y
- 20.31%
- 3Y*
- 7.90%
- 5Y*
- 6.87%
- 10Y*
- 3.21%
- ALL TIME*
- 5.06%
ALNY
- 1D
- 0.02%
- 1M
- -34.29%
- 6M
- -39.21%
- YTD
- -48.32%
- 1Y
- -48.85%
- 3Y*
- 2.82%
- 5Y*
- 2.81%
- 10Y*
- 11.28%
- ALL TIME*
- 17.20%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $567.18M | $557.43M | $409.61M | |
| $189.49M | $272.86M | $184.93M |
IONS vs. ALNY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
IONS Ionis Pharmaceuticals, Inc. | -34.56% | 126.29% | -30.90% | 33.94% | 24.12% | -46.18% | -6.41% | 11.75% | 7.48% | 5.16% |
ALNY Alnylam Pharmaceuticals, Inc. | -48.32% | 68.99% | 22.94% | -19.46% | 40.14% | 30.48% | 12.85% | 57.96% | -42.61% | 239.34% |
Correlation
The correlation between IONS and ALNY is 0.40, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.40 |
Correlation (3Y) Balances recent behavior with more history. | 0.46 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.46 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.46 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 2004 | 0.47 |
Fundamentals
IONS:
$8.60B
ALNY:
$27.44B
IONS:
-$3.46
ALNY:
$5.88
IONS:
9.67
ALNY:
5.88
IONS:
19.47
ALNY:
20.98
IONS:
$873.76M
ALNY:
$4.80B
IONS:
$857.70M
ALNY:
$1.88B
IONS:
$4.33B
ALNY:
$822.65M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IONS vs. ALNY — Risk / Return Rank
IONS
ALNY
IONS vs. ALNY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ionis Pharmaceuticals, Inc. (IONS) and Alnylam Pharmaceuticals, Inc. (ALNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IONS | ALNY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.46 | ||
| Sortino ratioReturn per unit of downside risk | +2.38 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 0.78 | +0.37 |
| Calmar ratioReturn relative to maximum drawdown | 0.51 | -0.82 | +1.33 |
| Martin ratioReturn relative to average drawdown | 1.64 | -1.68 | +3.32 |
Loading charts...
Drawdowns
IONS vs. ALNY - Drawdown Comparison
The maximum IONS drawdown since its inception was -91.42%, which is greater than ALNY's maximum drawdown of -83.58%. Use the drawdown chart below to compare losses from any high point for IONS and ALNY.
Loading charts...
Drawdown Indicators
| IONS | ALNY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.42% | -83.58% | -7.84% |
Max Drawdown (1Y)Largest decline over 1 year | -40.15% | -58.17% | +18.02% |
Max Drawdown (3Y)Largest decline over 3 years | -52.36% | -58.17% | +5.81% |
Max Drawdown (5Y)Largest decline over 5 years | -52.36% | -58.17% | +5.81% |
Max Drawdown (10Y)Largest decline over 10 years | -70.39% | -59.95% | -10.44% |
Current DrawdownCurrent decline from peak | -40.15% | -58.16% | +18.01% |
Average DrawdownAverage peak-to-trough decline | -52.26% | -30.66% | -21.60% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.53% | 28.31% | -15.78% |
Volatility
IONS vs. ALNY - Volatility Comparison
The current volatility for Ionis Pharmaceuticals, Inc. (IONS) is 29.82%, while Alnylam Pharmaceuticals, Inc. (ALNY) has a volatility of 35.07%. This indicates that IONS experiences smaller price fluctuations and is considered to be less risky than ALNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IONS | ALNY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 29.82% | 35.07% | -5.25% |
Volatility (6M)Calculated over the trailing 6-month period | 35.47% | 41.89% | -6.42% |
Volatility (1Y)Calculated over the trailing 1-year period | 52.79% | 47.33% | +5.46% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.75% | 50.53% | -6.78% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 45.64% | 54.28% | -8.64% |
Dividends
IONS vs. ALNY - Dividend Comparison
Neither IONS nor ALNY has paid dividends to shareholders.
Financials
IONS vs. ALNY - Financials Comparison
This section allows you to compare key financial metrics between Ionis Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
IONS vs. ALNY - Profitability Comparison
IONS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Ionis Pharmaceuticals, Inc. reported a gross profit of 265.21M and revenue of 267.95M. Therefore, the gross margin over that period was 99.0%.
ALNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of -956.05M and revenue of 1.29B. Therefore, the gross margin over that period was -74.1%.
IONS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Ionis Pharmaceuticals, Inc. reported an operating income of -102.29M and revenue of 267.95M, resulting in an operating margin of -38.2%.
ALNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 231.44M and revenue of 1.29B, resulting in an operating margin of 17.9%.
IONS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Ionis Pharmaceuticals, Inc. reported a net income of -114.65M and revenue of 267.95M, resulting in a net margin of -42.8%.
ALNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 164.49M and revenue of 1.29B, resulting in a net margin of 12.7%.
Frequently Asked Questions
IONS and ALNY have a correlation of 0.40, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ALNY has higher volatility (35.07%) compared to IONS (29.82%). In terms of maximum drawdown, IONS dropped -91.42% vs ALNY's -83.58%.
IONS currently has the higher Sharpe Ratio (0.39 vs -1.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IONS and ALNY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer